Loading...
Market
What will be the EU approval status of ALXN-1840 by end of 2025?
2
Monopar Therapeutics•Alexion Pharmaceuticals•AstraZeneca Rare Disease•Wilson Disease•Monopar•ALXN•Phase•Alexion•AstraZeneca
Resolution / Starting Odds
Approved • 25%
Rejected • 25%
Pending • 25%
Withdrawn • 25%
European Medicines Agency announcements
Story
Monopar Therapeutics Stock Surges 137% After Agreement for ALXN-1840, Phase 3 Drug for Wilson Disease
Oct 24, 2024, 04:08 PM
Monopar Therapeutics (NASDAQ: MNPR) has announced a significant agreement with Alexion Pharmaceuticals and AstraZeneca Rare Disease for its late-stage drug candidate targeting Wilson Disease. Following the announcement, Monopar's stock surged approximately 137%, prompting a trading halt due to volatility. The agreement grants Monopar an exclusive worldwide license to ALXN-1840, a drug candidate for Wilson Disease that has already completed a Phase 3 clinical trial. The stock was up about 20% ahead of Thursday's trading session, reflecting investor optimism regarding the potential of the drug and the strategic collaboration with Alexion and AstraZeneca.
View original story
Similar markets
Approved • 25%
Conditional Approval • 25%
Not Approved • 25%
Approval Pending • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Yes • 50%
No • 50%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
